Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION

Pharmacokinetics of Murine Anti-Human CD3 Antibodies in Man Are Determined by the Disappearance of Target Antigen

R. T. Meijer, R. P. Koopmans, I. J. M. ten Berge and P. T. A. Schellekens
Journal of Pharmacology and Experimental Therapeutics January 2002, 300 (1) 346-353; DOI: https://doi.org/10.1124/jpet.300.1.346
R. T. Meijer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. P. Koopmans
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
I. J. M. ten Berge
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P. T. A. Schellekens
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Therapy with monoclonal antibodies (mAbs) is characterized by a molar ratio of receptor to drug that is higher than usual in pharmacotherapy. As a consequence, changes in the amount of receptors induced by the therapy may have important consequences for pharmacokinetics. We therefore analyzed the pharmacokinetics and pharmacodynamics of an experimental therapeutic CD3 antibody, CLB-T3/4.A (murine IgA), which was given as a rejection treatment to renal transplant patients. Patients were treated with 5 mg of the mAb, as a daily bolus injection, during 10 days. Mean trough levels of mAbs increased during the 1st week, and decreased thereafter. However, about one-third of the patients had continuously rising trough levels and about one-third displayed a steady state, that was reached only after 4 days. On the first day of treatment, mAb concentrations showed a biphasic plasma disappearance curve. On subsequent days, monophasic plasma disappearance curves were observed with mean half-lives of 6 to 8 h. Administration of the mAb induced disappearance of target antigen from the peripheral blood, which could explain the difference in kinetics between day 1 and subsequent days shown by a simulation of the multidose curve of plasma concentrations, based on target antigen depletion. We conclude that at this dose the pharmacokinetics of CLB-T3/4.A were to a great extent determined by antibody-induced changes in antigen in peripheral blood. Moreover, determinations of pharmacokinetic and pharmacodynamic parameters based on single-dose data and traditional compartment models were inadequate for the purpose of prediction and extrapolation.

  • Abbreviations

    mAbs
    monoclonal antibodies
    ELISA
    enzyme-linked immunosorbent assay
    HAMAs
    human anti-mouse antibodies
    PBMC
    mononuclear cells from peripheral blood
    TCR
    T cell receptor
    FACS
    fluorescence-activated cell sorter
    FITC
    fluorescein isothiocyanate
    MFI
    mean fluorescence intensities
    PBS
    phosphate-buffered saline
    • Received March 2, 2001.
    • Accepted August 2, 2001.
    • The American Society for Pharmacology and Experimental Therapeutics
    View Full Text

    JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

    Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

     

    • Click here for information on institutional subscriptions.
    • Click here for information on individual ASPET membership.

     

    Log in using your username and password

    Forgot your user name or password?

    Purchase access

    You may purchase access to this article. This will require you to create an account if you don't already have one.
    PreviousNext
    Back to top

    In this issue

    Journal of Pharmacology and Experimental Therapeutics: 300 (1)
    Journal of Pharmacology and Experimental Therapeutics
    Vol. 300, Issue 1
    1 Jan 2002
    • Table of Contents
    • About the Cover
    • Index by author
    Download PDF
    Article Alerts
    Sign In to Email Alerts with your Email Address
    Email Article

    Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

    NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

    Enter multiple addresses on separate lines or separate them with commas.
    Pharmacokinetics of Murine Anti-Human CD3 Antibodies in Man Are Determined by the Disappearance of Target Antigen
    (Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
    (Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Citation Tools
    Research ArticleABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION

    Pharmacokinetics of Murine Anti-Human CD3 Antibodies in Man Are Determined by the Disappearance of Target Antigen

    R. T. Meijer, R. P. Koopmans, I. J. M. ten Berge and P. T. A. Schellekens
    Journal of Pharmacology and Experimental Therapeutics January 1, 2002, 300 (1) 346-353; DOI: https://doi.org/10.1124/jpet.300.1.346

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    Share
    Research ArticleABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION

    Pharmacokinetics of Murine Anti-Human CD3 Antibodies in Man Are Determined by the Disappearance of Target Antigen

    R. T. Meijer, R. P. Koopmans, I. J. M. ten Berge and P. T. A. Schellekens
    Journal of Pharmacology and Experimental Therapeutics January 1, 2002, 300 (1) 346-353; DOI: https://doi.org/10.1124/jpet.300.1.346
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Jump to section

    • Article
      • Abstract
      • Experimental Procedures
      • Results
      • Discussion
      • Acknowledgments
      • Abbreviations
      • References
    • Figures & Data
    • Info & Metrics
    • eLetters
    • PDF

    Related Articles

    Cited By...

    More in this TOC Section

    • Transport Is Not Rate-Limiting in Morphine Glucuronidation in the Single-Pass Perfused Rat Liver Preparation
    • Enhanced Hepatic Uptake and Bioactivity of Type α1(I) Collagen Gene Promoter-Specific Triplex-Forming Oligonucleotides after Conjugation with Cholesterol
    • Characterization of P-glycoprotein Inhibition by Major Cannabinoids from Marijuana
    Show more ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION

    Similar Articles

    Advertisement
    • Home
    • Alerts
    Facebook   Twitter   LinkedIn   RSS

    Navigate

    • Current Issue
    • Fast Forward by date
    • Fast Forward by section
    • Latest Articles
    • Archive
    • Search for Articles
    • Feedback
    • ASPET

    More Information

    • About JPET
    • Editorial Board
    • Instructions to Authors
    • Submit a Manuscript
    • Customized Alerts
    • RSS Feeds
    • Subscriptions
    • Permissions
    • Terms & Conditions of Use

    ASPET's Other Journals

    • Drug Metabolism and Disposition
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    ISSN 1521-0103 (Online)

    Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics